Oramed Pharmaceuticals Inc. income statement

In fiscal 2025, Oramed Pharmaceuticals Inc. reported revenue of $2.0m, up 49.3% on the year before, operating income of −$15.1m (a -754.4% margin) and net income of $64.0m, or $1.50 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Oramed Pharmaceuticals Inc.: income statement, annual
Fiscal year	2016Aug 2016	2017Aug 2017	2018Aug 2018	2019Aug 2019	2020Aug 2020	2021Aug 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Revenue	1	2	2	3	3	3	3	1	2
Cost of revenue	0	0	−0	0	—	—	—	—	2
Gross profit	0	2	3	3	—	—	—	—	0
Research and development	8	10	12	14	10	21	28	9	6
General and administrative	2	3	4	4	4	6	14	8	9
Operating income	−10	−11	−14	−15	−12	−24	−41	−16	−15
Interest expense	—	—	—	—	—	—	—	2	—
Income before tax	−10	−10	−13	−14	−12	—	−38	5	75
Income tax	1	0	—	0	—	—	0	—	11
Net income	−11	−10	−13	−14	−12	−23	−37	5	64
Diluted EPS	$0.87	$0.79	$0.86	$0.82	$0.56	$0.78	−$0.94	$0.14	$1.50
Diluted shares (average)	13m	13m	15m	17m	21m	28m	39m	41m	42m
EBITDA	−10	−11	−14	−15	−12	−24	−41	−16	−15

US$ millions unless shown otherwise. Fiscal quarters.

Oramed Pharmaceuticals Inc.: income statement, quarterly
Quarter	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025
Revenue	1	1	0	0	2	0	0	0
Cost of revenue	—	—	—	—	2	0	0	0
Gross profit	—	—	—	—	0	0	0	0
Research and development	4	2	1	2	2	1	1	2
Selling and marketing	0	0	−1	—	—	—	—	—
General and administrative	1	2	3	2	2	1	1	4
Operating income	−5	−4	−3	−4	−5	−2	−2	−6
Interest expense	—	—	1	1	—	—	—	—
Income before tax	—	−1	−3	13	−7	13	59	10
Income tax	—	—	—	—	1	−0	11	−0
Net income	−3	−1	−3	13	−8	13	48	10
Diluted EPS	−$0.08	−$0.03	−$0.08	$0.33	−$0.19	$0.31	$1.13	$0.24
EBITDA	−5	−4	−3	−4	−4	−2	−2	−6

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KRSA vs ORMP MCRB vs ORMP CLGN vs ORMP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Oramed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Oramed Pharmaceuticals Inc.